> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# FDA Seeks Industry Data for Kidney Biomarker Initiative
- URL: https://www.fdaweb.com/fda-seeks-industry-data-for-kidney-biomarker-initiative/
- Published: 2026-06-08T12:00:00.000Z
- Updated: 2026-09-14T13:40:43.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5161270

FDA is launching a new effort to aggregate clinical trial data on kidney safety biomarkers, seeking pharmaceutical industry participation in a pilot program that could ultimately broaden the agency's use of novel a "biomarker incubator," a regulatory science initiative designed to collect and analyze biomarker data across multiple drug development programs, according to a [*Federal Register* ](https://www.federalregister.gov/documents/2026/05/13/2026-09533/biomarker-incubator-urinary-kidney-safety-biomarkers-request-for-information?utm%5Fmedium=email&utm%5Fsource=govdelivery)notice. Under the program, the agency is requesting voluntary submissions of deidentified human data related to urinary biomarkers used to detect drug-induced kidney injury (DIKI), an area where regulators and drug developers have long sought more sensitive measures of toxicity.

The effort signals FDA's growing interest in leveraging large, pooled datasets to evaluate emerging biomarkers outside the agency's formal qualification pathway established under the 21st Century Cures Act. For industry, the initiative could provide a new mechanism for advancing biomarkers that have generated data across individual development programs but have not progressed through the resource-intensive qualification process. FDA’s notice says the incubator is intended to complement, rather than replace, existing biomarker qualification efforts.

The pilot project focuses on six urinary kidney safety biomarkers — kidney injury molecule-1 (KIM-1), cystatin C, osteopontin, N-acetyl-β-D-glucosaminidase (NAG), neutrophil gelatinase-associated lipocalin (NGAL), and clusterin — that have attracted increasing attention as potential early indicators of renal toxicity.

A consortium led by the Foundation for the National Institutes of Health Biomarkers Consortium and the Critical Path Institute previously secured FDA qualification of a panel of kidney injury biomarkers in 2018 for use alongside conventional renal safety measures in Phase 1 studies involving healthy volunteers. Since then, stakeholders have continued to push for broader adoption of biomarker-based approaches capable of identifying kidney injury before traditional laboratory markers show clinically significant changes, according to the agency.

FDA says its pilot will evaluate the availability and quality of existing biomarker data, characterize variability across patients and clinical settings, assess assay performance, and compare biomarker signals against conventional measures of kidney function. The agency also plans to establish infrastructure for requesting, receiving, storing and analyzing biomarker datasets.

The initiative arrives as regulators increasingly explore how pooled clinical datasets can support development of novel endpoints and accelerate drug development. FDA notes that biomarker data are often generated during clinical development but remain fragmented across individual programs, collected using different protocols, and frequently are not submitted to regulators in standardized formats. Those limitations have historically complicated efforts to establish robust evidence supporting biomarker use across therapeutic areas.